Fact-checked by Grok 2 weeks ago

Celotex

Celotex Corporation was an American manufacturer and distributor of roofing, , and building products, founded in 1920 in , , as a subsidiary of the Manufacturing Company to produce its namesake Celotex from , a byproduct of processing. The company innovated cost-effective thermal and acoustic materials that gained widespread use in construction during the early , later expanding into -containing products such as , siding, and pipe , which were marketed for their resistance and durability. Acquired and restructured under Jim Walter Corporation in the , Celotex faced escalating legal challenges in the over worker and consumer exposures to fibers in its products, linked to diseases including and ; these claims, numbering in the tens of thousands, precipitated the company's Chapter 11 bankruptcy filing on October 12, 1990. Post-bankruptcy, Celotex's operations ceased, its assets were liquidated, and the Celotex was established to compensate verified claimants, distributing billions in payments while highlighting the long-term liabilities of use in industrial manufacturing.

Founding and Early Operations

Establishment as Bagasse Fiberboard Innovator

Celotex Corporation was founded in 1920 in Chicago, Illinois, as the first company to produce commercial fiberboard from bagasse, the fibrous residue left after sugarcane juice extraction. This breakthrough utilized an abundant agricultural byproduct, transforming waste from sugarcane mills into a viable building material through a felting process that created dense, insulating boards. The innovation addressed the limitations of wood-based fiberboards by leveraging a renewable, low-cost resource prevalent in sugarcane-producing regions, enabling scalable production for insulation applications. The company established its primary manufacturing plant in , near New Orleans, in 1921, strategically locating operations amid the U.S. Gulf Coast's sugarcane industry to secure raw supplies. At this facility, was processed by cooking, refining into fibers, and forming into sheets under heat and pressure, yielding products with superior thermal resistance compared to earlier alternatives. Initial output focused on rigid insulation boards, marketed for use in walls, roofs, and floors, with densities tailored for specific load-bearing and insulating needs—typically ranging from 15 to 30 pounds per cubic foot. Early Celotex fiberboards gained traction in for their fire resistance, pest deterrence, and acoustic properties, without reliance on scarce timber resources. By the mid-1920s, the Marrero plant's capacity supported nationwide distribution, establishing Celotex as a leader in non-wood innovation and spurring operations, including imports to . This foundation in bagasse-based manufacturing positioned the company for broader expansion into building products, emphasizing empirical advantages in cost and performance over traditional materials.

Expansion into Insulation Markets

In the early 1920s, following the development of its flagship Celotex Insulating Lumber—a rigid cellulose fiberboard produced from bagasse via a felting process—Celotex scaled production at its New Orleans facility to capitalize on demand for thermal and acoustic insulation in residential and commercial construction. This product, introduced around 1920, served primarily as roof insulation, exterior sheathing, and plaster bases, offering superior insulating properties compared to traditional wood or plaster alternatives due to its low density and fiber structure. By prioritizing bagasse sourcing from Louisiana sugar mills, the company achieved cost efficiencies that enabled competitive pricing and rapid market penetration in the U.S. building sector, where insulation needs were rising amid post-World War I construction booms. To broaden its reach, Celotex established the Celotex Company of in 1925 as a , initially operating from offices in to distribute boards, roofing felts, and siding materials throughout . This move addressed growing transatlantic demand for lightweight, fire-resistant building products, leveraging the U.K.'s rebuilding efforts and export networks. By , the had opened a manufacturing plant at Stonebridge , enabling localized production and customization of variants tailored to climates and standards, which further solidified Celotex's position in international markets. Domestic expansion complemented these efforts, with Celotex diversifying its insulation portfolio to include specialized boards for walls and ceilings, while maintaining a focus on non-mineral fiber compositions to differentiate from competitors reliant on costlier or less sustainable materials. Sales growth in the insulation segment drove investments in additional U.S. plants and R&D for enhanced durability, such as moisture-resistant formulations, positioning the company as a leader in fiberboard-based thermal barriers by the mid-20th century. This strategic emphasis on —rather than solely structural products—yielded significant revenue, with the sector comprising the core of early operations before broader construction material lines emerged.

Product Development and Manufacturing

Non-Asbestos Product Lines

Celotex Corporation initially specialized in bagasse-based products, marking its entry into building materials as an innovator in sustainable alternatives derived from . The company's foundational product, Celotex Insulating Lumber, was introduced in 1921 as a manufactured from , the fibrous residue left after sugar extraction from stalks. This material was produced through a felting process that compressed and bonded the fibers without chemical binders, resulting in rigid panels suitable for thermal and structural applications. These non-asbestos fiberboards were fabricated at Celotex's New Orleans, Louisiana facility, with standard dimensions of 7/16-inch thickness, 4 feet in width, and lengths ranging from 8 to 12 feet, weighing approximately 60 pounds per 100 square feet. Primarily used as exterior sheathing for walls and roofs, the boards provided value while serving as a base for or siding; they were also employed in interior partitions, ceilings, and early acoustic applications such as Acousti-Celotex Cane Tile for sound absorption in buildings. The composition offered advantages in moisture resistance and ease of compared to traditional wood-based alternatives, contributing to widespread adoption in residential and commercial construction during the and . Expansion of the non-asbestos line included variations optimized for specific uses, such as insulating sheathing boards that prioritized without relying on mineral additives. These products underscored Celotex's early focus on resource-efficient , leveraging abundant byproducts from Louisiana's agricultural sector to produce cost-effective, lightweight panels that met growing demand for affordable prior to the widespread integration of in later decades.

Incorporation of Asbestos in Building Materials

Celotex Corporation incorporated asbestos fibers into certain building materials primarily to improve fire resistance, thermal insulation, and structural durability, properties valued in construction applications during the mid-20th century. This practice began in the 1920s, with products such as Celotex Excel Block insulation containing asbestos from 1925 to approximately 1960. Asbestos content typically comprised a small percentage of the composition, often combined with cement, cane fiber, or other binders in sheets, boards, and blocks. Key asbestos-containing products included Vitricel Asbestos Sheets and Vitricel Cement formulations, manufactured from 1941 to around 1960, used for fire-retardant sheathing and roofing underlayment. Cemesto panels, introduced by the , featured asbestos-cement composites in thicknesses of 1 1/8 to 2 inches for wall and roof applications, advertised for their hardness and heat resistance as early as 1943. Roofing and insulation variants also incorporated for weatherproofing and , with production spanning into the 1970s. The 1978 acquisition of Manufacturing Company expanded Celotex's product portfolio, integrating Carey's established lines such as block and fiberock felt, which dated back to the early 1900s but continued under Celotex until the 1980s. was sourced from Carey Canada mines, operational from at least 1933 until closure in 1986, supplying raw fibers for milling and integration into Celotex formulations. Manufacturing ceased use in most products by the mid-1980s amid emerging regulatory pressures and litigation, though legacy materials persisted in the market.

Empirical Evidence on Exposure Risks

Empirical studies of workers handling , the predominant form incorporated into Celotex and products, indicate elevated risks of respiratory diseases at high cumulative exposures, typically exceeding 25 fiber-years. For instance, analyses of and workers exposed primarily to chrysotile report standardized mortality ratios for increasing with dose, though synergies with cigarette smoking account for much of the observed excess. incidence remains low in such populations compared to those exposed to varieties like crocidolite, with chrysotile's lower biopersistence linked to reduced pleural retention and carcinogenicity. Dose-response modeling from occupational data often assumes without a , projecting risks even at low levels such as 4 fiber-years, where relative risk approximates 1.9. However, mechanistic and epidemiologic reviews of chrysotile-specific exposures, including in electrical and trades, identify thresholds below which no significant mesothelioma or elevation occurs, attributed to the mineral's rapid clearance from lung tissue and absence of cleavage fragments. and animal studies reinforce this, showing distinct response patterns for versus amphiboles, with no genotoxic effects at environmentally relevant doses. For non-occupational or bystander exposures relevant to Celotex building materials—such as undisturbed pipe or roofing—empirical detects negligible release, correlating with minimal . Population studies of residents near sites or in homes with intact report no consistent cancer excess, contrasting with high-dose industrial settings. Short-term or low-intensity disturbances, absent friable degradation, yield concentrations orders of magnitude below occupational thresholds, underscoring causation challenges without quantifiable dose metrics. Confounding factors, including traces in some deposits (though rare in commercial ), further complicate attributions to pure products like those from Celotex.

Distinctions Between Asbestos Types and Causation Challenges

Asbestos minerals are categorized into two primary groups: and . asbestos consists solely of , characterized by curly, flexible fibers that are shorter and more readily cleared from the s due to their magnesium silicate structure and lower biopersistence. In contrast, asbestos includes varieties such as amosite and crocidolite, featuring straight, needle-like fibers that are longer, more durable, and resistant to dissolution in biological environments, leading to prolonged retention in . These structural distinctions underpin differential health risks, with empirical studies indicating that poses substantially lower carcinogenic potency compared to , particularly for . Quantitative analyses of epidemiological data reveal marked potency differences. A by Hodgson and Darnton estimated 's mesothelioma potency at approximately 0.1% to 1% of fibers, while for , 's risk was 10 to 50 times lower than that of amphiboles like crocidolite or amosite. Subsequent potency modeling by Berman and Crump corroborated this, assigning amphiboles over 200 times greater mesothelioma potency relative to , based on studies isolating fiber types. Celotex Corporation's products, including insulation and coverings, predominantly incorporated , as confirmed by environmental sampling at former sites showing minimal contamination. These findings challenge blanket attributions of equivalent hazard across asbestos types, emphasizing fiber-specific kinetics: fibers degrade faster via acid attack on layers, reducing translocation to mesothelial surfaces. Causation challenges arise from difficulties in retrospectively identifying fiber types in mixed exposures, quantifying historical doses, and isolating from confounders like , which synergistically elevates risk but not . In chrysotile-only cohorts, such as workers, excess risks correlate with high cumulative exposures exceeding 100 fiber-years/ml, with no observed at lower levels, suggesting thresholds absent in data. causation further hinges on fiber dimensions—long, thin fibers (>5 μm) penetrate pleura more effectively—yet diagnostic tissues often lack , complicating specific attribution in litigation. Latency periods of 20-50 years exacerbate , while regulatory frameworks treating all as equipotent overlook these empirical gradients, potentially overstating risks for chrysotile-dominant products like those of Celotex. Peer-reviewed distinctions thus underscore the need for exposure-specific assessments over generalized liability.

Onset of Asbestos Litigation in the 1980s

The earliest documented asbestos-related lawsuits against Celotex Corporation emerged in 1980, coinciding with a broader surge in claims against asbestos manufacturers as medical evidence linking exposure to diseases like and gained traction. In February 1980, a instituted against Celotex and other defendants in state court, alleging from asbestos exposure; the case proceeded to in 1986, highlighting early disputes over causation and product identification. A prominent federal case, Celotex Corp. v. Catrett, was filed in September 1980 by Dorothy Catrett, administratrix of her husband Louis Catrett's estate, in the U.S. District Court for the District of Columbia. The complaint asserted wrongful death claims against Celotex for negligence, breach of warranty, and strict liability, based on Louis Catrett's exposure to Celotex asbestos products while working as a boiler insulation salesman in Chicago during 1970–1971, which allegedly contributed to his 1979 death from lung cancer. The district court granted summary judgment to Celotex in 1982 for lack of evidence tying the product to the decedent's exposure, but the D.C. Circuit reversed in 1985, prompting Supreme Court review. In a 1986 decision, the Court vacated the reversal and remanded, holding that a defendant moving for summary judgment need not produce evidence negating the plaintiff's case if the plaintiff lacks sufficient proof of an essential element, such as specific product exposure—a ruling that influenced procedural standards in subsequent asbestos mass torts by easing defendants' burdens in challenging weak claims. These initial suits marked the onset of escalating litigation, with thousands of asbestos-related and claims filed against Celotex nationwide by the late 1970s and early 1980s, primarily from insulators, shipyard workers, and trades exposed to products like asbestos-cement boards, , and . By mid-decade, claims had proliferated amid industry-wide trends, including punitive damage demands in multidistrict litigation, as seen in consolidated cases seeking recovery from Celotex for failure-to-warn and design defects. Celotex defended vigorously, often contesting exposure specificity and causation, but the volume—reaching thousands of suits through the 1980s—strained resources, with liabilities mounting from verdicts, settlements, and defense costs. The decade's litigation wave reflected growing plaintiff success rates, driven by evidentiary rulings favoring survivors' accounts over strict proof requirements, though Celotex and peers argued many claims lacked robust causal links beyond mere presence of asbestos in workplaces. By 1989, cumulative pressures foreshadowed insolvency, culminating in Chapter 11 filing in 1990 amid estimates of hundreds of thousands of pending or potential claims.

Bankruptcy Filing and Reorganization in 1990

On October 12, 1990, Celotex Corporation and its affiliate Carey Canada Incorporated filed voluntary petitions for reorganization under Chapter 11 of the Code in the Court for the Middle District of , Tampa Division (Case No. 90-10016). The filing was driven by escalating asbestos-related liabilities, including over 100,000 pending claims and substantial property damage litigation, with the companies having already disbursed more than $587 million in settlements and defense costs since asbestos suits began in the 1970s. This overwhelmed Celotex's operational and resources, as the firm anticipated further waves of claims tied to its historical use of in products like and . The immediate effect of the petitions was the invocation of the Bankruptcy Code's automatic stay under 11 U.S.C. § 362(a), which suspended all ongoing and future lawsuits against Celotex and , providing a breathing spell to assess assets, negotiate with creditors, and formulate a viable strategy. Assets at filing included manufacturing facilities, inventory, and insurance policies valued in the hundreds of millions, though much of the value hinged on litigating coverage disputes with insurers over exclusions. The proceedings centralized claim estimation, with the court appointing claimants' committees to represent and interests, marking a shift from fragmented state court battles to a unified process aimed at equitable distribution. Reorganization efforts focused on preserving the core non-asbestos business—renamed the Celotex Corporation post-filing—while segregating liabilities into dedicated trusts funded by company stock, future earnings contributions, and recoveries. Early challenges included valuing the torrent of claims, with estimates exceeding 500,000 potential filings, and resolving inter-creditor disputes over priority between asbestos victims, trade creditors, and insurers reluctant to pay without proof of non-exclusion coverage. By 1990's end, the debtors proposed channeling all asbestos claims through trusts to allow business continuity, a model that influenced subsequent mass-tort bankruptcies but faced delays from appeals and empirical disputes over causation and levels in Celotex products. The process underscored causal complexities in litigation, where friable fibers posed higher risks than the variants sometimes used by Celotex, yet courts often aggregated claims without granular differentiation.

Asbestos Settlement Trust

Establishment and Initial Funding

The Celotex Settlement Trust was established on February 1, 1998, as a statutory under the confirmed Second Amended and Restated Joint Plan of Reorganization for Celotex Corporation and Carey Canada Inc., following their Chapter 11 petitions filed on October 12, 1990, in the United States Bankruptcy Court for the Middle District of . The creation of the trust was mandated by Section 524(g) of the U.S. Bankruptcy Code to centralize and resolve present and future asbestos claims against the debtors, channeling such liabilities away from the reorganized entities while providing compensation to eligible claimants through structured distribution procedures. This mechanism allowed Celotex to emerge from in 1996, with ongoing operations insulated from further mass tort litigation. Initial funding for the trust totaled approximately $1.5 billion, comprising cash, securities, and other assets transferred from the reorganized debtors, including a significant portion derived from the equity value of the successor company, Jim Walter Corporation (later rebranded). Under the reorganization plan, the debtors contributed these resources to ensure the trust's capacity to pay claims over time, with trustees appointed to administer distributions based on predefined disease categories, exposure criteria, and payment percentages adjusted periodically for solvency. The funding structure prioritized long-term viability, reserving a portion for future demands while prohibiting dissipation through excessive early payouts.

Ongoing Operations and Recent Adjustments

The Celotex Settlement Trust maintains ongoing operations focused on evaluating, liquidating, and compensating valid claims arising from to asbestos-containing products manufactured by Celotex Corporation, in accordance with its Claims Procedures and Trust Distribution Procedures. Claims are processed through an online portal that allows submission, tracking, and deficiency , with prioritization for Discounted Payment (DCP) elections over Individualized Claims (IRC) when filed concurrently. DCP provides fixed scheduled values by category for expedited , while IRC involves case-specific valuation of gross settlement amounts subject to the current payment percentage. The trust conducts audits and medical reviews to verify and , aiming to equitably allocate resources between present and future claimants without depleting assets prematurely. In June 2023, the adjusted its IRC to 7% of the gross settlement value and modified DCP parameters, reflecting actuarial assessments to sustain long-term payouts amid claim volumes exceeding initial projections. This reduction from prior levels, such as 8% in 2021, responds to the need for conservative fund management, as trusts must reserve sufficient assets for anticipated future demands estimated under Bankruptcy Code section 524(g). The DCP scheduled values post-adjustment include $6,800 for , $1,750 for , and lower tiers for non-malignant conditions, ensuring faster but capped compensation. Further operational refinements occurred in October 2024 with the adoption of a Deemed Withdrawn Policy, under which claims inactive for extended periods—due to unresolved deficiencies or lack of claimant response—are automatically withdrawn to streamline and reduce administrative . Effective January 1, 2025, the trust implemented a deferral period for certain payments, suspending disbursements temporarily to preserve liquidity and prevent , a measure calibrated via duties to balance claimant equity. In January 2025, a policy was introduced, permitting deletion of records beyond statutory limits to control costs while complying with legal preservation requirements. These adjustments underscore the trust's adaptive response to fiscal pressures, including over $30 billion in asbestos trust liabilities industry-wide as of 2025, without additional infusions beyond the original $1.5 billion funding from the 1990-1998 reorganization.

Industry Legacy and Policy Impact

Innovations and Contributions to Construction Efficiency

The Celotex pioneered the commercial production of from , the fibrous residue of processing, beginning in 1920. This innovation utilized an abundant agricultural byproduct from Louisiana's industry, enabling the manufacture of lightweight, cost-effective insulating through a felting process that compressed fibers into rigid boards. These boards offered superior compared to traditional materials like wood sheathing, reducing heat loss in buildings and thereby enhancing in projects during the 1920s and 1930s. Celotex expanded its bagasse-based products to include sheathing, roofing felts, and wallboards, which were treated for resistance to fungi, , and moisture, facilitating faster installation and durability in humid climates. By repurposing waste material, the company lowered production costs relative to virgin wood or alternatives, allowing broader adoption in residential and commercial builds and contributing to streamlined supply chains in the building materials sector. This approach not only minimized reliance on scarce timber resources but also supported scalable , as evidenced by the company's growth into multiple product lines by the mid-20th century. A notable advancement was the development of Cemesto board in , a prefabricated featuring a Celotex cane-fiber core sealed and coated with for structural integrity and weather resistance. Introduced commercially around , Cemesto enabled rapid assembly in housing , as demonstrated in a 1933 experimental home using similar panels, which reduced on-site labor and compared to stick-built methods. These innovations collectively advanced efficiency by promoting , resource-efficient materials, and improved thermal performance, influencing standards for insulated building envelopes prior to widespread regulatory shifts.

Influence on Tort Law, Regulation, and Asbestos Policy Debates

The decision in Celotex Corp. v. Catrett, 477 U.S. 317 (1986), significantly shaped litigation procedures by clarifying the standards for under Federal Rule of Civil Procedure 56. Arising from an wrongful death suit filed by Dorothy Catrett against Celotex after her husband's 1979 death from malignant , the case addressed whether Celotex, as the movant, needed to negate the plaintiff's claim or merely demonstrate the absence of supporting it. The Court, in a 6-3 ruling authored by Rehnquist, held that the moving party bears no burden to produce disproving the non-movant's case; instead, the non-movant must then show specific facts evidencing a genuine issue for trial, rejecting stricter pre-1980s interpretations that required affirmative negation. This decision, part of the 1986 trilogy alongside Anderson v. and Matsushita Electric Industrial Co. v. Zenith Radio Corp., expanded defendants' ability to dispose of unsupported claims early, particularly benefiting defendants in voluminous mass s where plaintiffs often struggled to link specific exposure to products. Celotex's 1990 Chapter 11 bankruptcy filing, driven by over 380,000 claims accumulating since the early 1980s, exemplified the mass system's strains and influenced subsequent legal mechanisms for handling such liabilities. The reorganization plan, confirmed in 1996, established the Celotex under 11 U.S.C. § 524(g), channeling all present and future claims into a $1.8 billion initial fund derived from company stock, insurance proceeds, and assets, with perpetual injunctions shielding the reorganized entity from further suits. This trust model, resolving claims via fixed categories and percentages (e.g., later adjusted to 35% by amid depletion), set precedents for over 30 similar §524(g) trusts, aggregating liabilities to prevent piecemeal litigation from destroying viable businesses while compensating victims through structured distributions exceeding $2 billion by the . However, the approach fueled debates over its efficiency, as uncoordinated trust payments risked under- or over-compensating claimants relative to solvent defendants in ongoing suits, prompting critiques of "double recovery" without judicial oversight. The Celotex experience contributed to broader policy controversies, underscoring how litigation waves—totaling $200 billion in estimated costs and 80+ corporate by 2000—exposed flaws in state-by-state adjudication for diffuse, long-latency exposures. Proponents of argued that bankruptcy trusts like Celotex's fragmented compensation, evading full evidentiary scrutiny and enabling strategic claim suppression or inflation, thus advocating national solutions such as victim compensation funds modeled on the 1988 Black Lung Benefits Act or proposed federal trusts to standardize payouts and halt forum-shopping. Critics, including insurers and remaining defendants, highlighted transparency deficits, where trusts disbursed billions opaquely (e.g., Celotex Trust payments totaling hundreds of millions annually by the 2000s), leading to legislative pushes like the 2005-2017 bills and the 2017 FACT Act for mandatory disclosures to prevent claim duplication. These debates emphasized causal challenges in attributing diseases to specific actors amid mixed exposures, favoring evidence-based criteria over expansive to balance victim redress with economic viability, though federal regulatory efforts like the EPA's 1989 partial ban remained distinct from -driven policy shifts.

References

  1. [1]
    Celotex Corporation - Asbestos Exposure and Legal Information
    The Celotex Corporation was founded in 1920 in Chicago, Illinois, as a subsidiary of Philip Carey Manufacturing Company. Celotex manufactured fiberboard ...
  2. [2]
    Celotex Corporation | Asbestos Products & Mesothelioma Trust Fund
    Jul 14, 2025 · In 1925, Celotex established a subsidiary called the Celotex Company of Great Britain, which distributed asbestos roofing, siding and ...
  3. [3]
    History of Celotex - Western roofing
    Jul 25, 2022 · When Celotex was founded in the early 1920s, it produced fiberboard insulation. As the company grew in subsequent decades, it expanded and made other ...
  4. [4]
    Celotex Corporation | Asbestos Products, Exposure, Trust Fund
    Sep 1, 2025 · Celotex was founded in the early 1920s in Chicago. It was a subsidiary of the Philip Carey Corporation. The subsidiary was formed to manufacture ...Celotex History and Asbestos · Which Workers Were at Risk of...
  5. [5]
    The History of Celotex Corporation and Carey Canada Incorporated
    Celotex, a Delaware corporation reincorporated in 1964, was a manufacturer and distributor of roofing and building products for residential and commercial use.
  6. [6]
    Asbestos Manufacturers Celotex Corp. - Vinson Law
    Jun 24, 2016 · In the 1920s the Celotex Corporation of America and its subsidiary Celotex Company of Great Britain established themselves in importing bagasse ...
  7. [7]
    Celotex® Products & History Complete history of Celotex, insulating ...
    Celotex Corporation produced the first fiberboard made from bagasse in 1920. (Jester 2014). Other records indicate that the company was founded a year later ...
  8. [8]
    Building with Bagasse - 64 Parishes
    Sep 1, 2024 · Celotex, a Marrero, Louisiana-based company, utilized sugar cane ... production into fiberboard in Marrero since 1921. As one of the ...
  9. [9]
    Celotex - MFA Cameo - Museum of Fine Arts Boston
    May 24, 2022 · A brand name for a variety of fiberboards made from Bagasse (sugar cane waste) and/or mineral fibers. The Celotex Company was founded in 1925.Missing: Corporation | Show results with:Corporation
  10. [10]
  11. [11]
    Early 20th-Century Building Materials: Fiberboard and Plywood
    Oct 15, 2016 · In 1921, a fiberboard was produced using bagasse, the dry pulp byproduct of sugar cane after the juice has been extracted. This fiberboard was ...
  12. [12]
    Celotex: Fiberboard Insulation, Asbestos Trust & Lawsuits
    Celotex manufactured asbestos insulation and construction materials from the 1920s to the 1980s, and it operated an asbestos mine until 1986.
  13. [13]
    [PDF] Health Consultation - NJ.gov
    Jan 10, 2007 · Sampling conducted at the Celotex site indicated the presence of mostly chrysotile asbestos ... However, OSHA continues to regulate chrysotile and ...
  14. [14]
    Dose-response-relationship between occupational exposure to ...
    There is a strong association between the level of exposure to DEE and the risk of lung cancer, which is doubled for workers exposed to a cumulative EC above ...
  15. [15]
    Low-dose exposure to asbestos and lung cancer - PubMed
    Lung cancer risk increased almost linearly with cumulative dose of asbestos. The risk at a cumulative dose of 4 fiber-years was 1.90 (95% confidence interval ( ...
  16. [16]
    Electricians' chrysotile asbestos exposure from electrical products ...
    The evidence does not indicate that exposure to chrysotile in electrical products causes mesothelioma or lung cancer in electricians.<|separator|>
  17. [17]
    Cause-Specific Mortality in Relation to Chrysotile-Asbestos ...
    All these studies together with our results support the hypothesis that chrysotile can cause mesothelioma, although the extent to which the potency of ...
  18. [18]
    Low-Dose Exposure to Asbestos and Lung Cancer: Dose-Response ...
    Lung cancer risk increased almost linearly with cumulative dose of asbestos. The risk at a cumulative dose of 4 fiber-years was 1.90 (95% confidence interval ( ...
  19. [19]
    Dose-Response Relationships in Expression of Biomarkers of Cell ...
    These studies reveal distinct dose-response patterns with different types of asbestos, suggesting a threshold for effects of chrysotile both in in vitro studies ...
  20. [20]
    Asbestos Exposure and Cancer Risk Fact Sheet - NCI
    May 20, 2021 · The EPA concluded that exposure to asbestos from some vermiculite products poses only a minimal health risk. The EPA recommended that consumers ...
  21. [21]
    Risk of cancer associated with residential exposure to asbestos ...
    In particular, there is no scientific evidence on the risk of cancer associated with living in a house containing loose-fill asbestos insulation. In Australia, ...
  22. [22]
    Asbestos | Public Health Statement | ATSDR - CDC
    Members of the public who are exposed to lower levels of asbestos may also have increased chances of getting cancer, but the risks are usually small and are ...
  23. [23]
    Short-Term Asbestos Exposure | How Much Is Harmful?
    Short-term exposure to asbestos dust can lead to mesothelioma and other forms of cancer. But unless the exposure is intense, the risk of cancer from short-term ...
  24. [24]
    The 6 Different Types of Asbestos Explained
    Small amounts of amphibole asbestos are often found in chrysotile deposits. These trace amounts increase its toxicity. But exposure to only chrysotile asbestos ...
  25. [25]
    Health risk of chrysotile revisited - PMC - PubMed Central
    This review provides a basis for substantiating both kinetically and pathologically the differences between chrysotile and amphibole asbestos.
  26. [26]
    The health effects of short fiber chrysotile and amphibole asbestos
    The first is the difference in biosolubility between the two mineral types chrysotile and amphibole asbestos. Amphibole asbestos is encased by a crystalline ...
  27. [27]
    The quantitative risks of mesothelioma and lung cancer in relation to ...
    The risk differential between chrysotile and the two amphibole fibres for lunc cancer is thus between 1:10 and 1:50.Missing: potency | Show results with:potency
  28. [28]
    Are Relative Potency Analyses Proof That Chrysotile Has Some ...
    Berman & Crump (2008) estimate the amphiboles were more than 200 times more potent than chrysotile.
  29. [29]
    The health effects of chrysotile: Current perspective based upon ...
    This review provides an important basis for substantiating both kinetically and pathologically the differences between chrysotile and amphiboles.
  30. [30]
    Quantitative assessment of mesothelioma and lung cancer risk ...
    Aug 1, 2023 · There is a widely held scientific consensus that amphibole asbestos is much more potent in relation to mesothelioma than chrysotile. In 2000, ...
  31. [31]
    An updated evaluation of reported no-observed adverse effect levels ...
    This analysis updates two previous analyses that evaluated the exposure-response relationships for lung cancer and mesothelioma in chrysotile-exposed cohorts.
  32. [32]
    Comparison of various methodological approaches to model ...
    May 12, 2025 · It seems clear that very short fibers are below the length threshold for mesothelioma. Chrysotile asbestos fibers recovered from lung tissue ...
  33. [33]
    [PDF] The Quantitative Risks of Mesothelioma and Lung Cancer ... - GOV.UK
    The risk differential between chrysotile and the two amphibole fibres for lung cancer is thus between 1:10 and 1:50.<|separator|>
  34. [34]
    A comparison of asbestos fiber potency and elongate mineral ...
    Dec 15, 2018 · In 2000, Hodgson and Darnton calculated the potency for amosite, crocidolite, and chrysotile to cause mesothelioma based on the current ...
  35. [35]
    Smith v. Celotex Corp. :: 1989 - Justia Law
    He instituted suit against GAF and several other asbestos manufacturing defendants on February 19, 1980. A jury trial was conducted from January 21, 1986 to ...
  36. [36]
    Celotex Corp. v. Catrett | 477 U.S. 317 (1986)
    In September, 1980, respondent administratrix filed this wrongful death action in Federal District Court, alleging that her husband's death in 1979 resulted ...Missing: onset | Show results with:onset
  37. [37]
    IMO The Liquidation of Integrity Ins. Co. v. Celotex Asbestos Trust
    In the late 1970s and early 1980s, thousands of asbestos-related claims were filed nationwide against Celotex for bodily injury and property damage. In 1990, ...
  38. [38]
    In Re Related Asbestos Cases, 566 F. Supp. 818 (N.D. Cal. 1983)
    In these asbestos-related personal injury cases, plaintiffs seek recovery of punitive damages against various defendants, including the Celotex Corporation, the ...
  39. [39]
    Celotex Corporation | Asbestos Exposure and Lawsuits
    Dec 31, 2024 · The Celotex Corporation was founded in the 1920s in Chicago as the Celotex Company of America, a subsidiary of Philip Carey Corporation. Celotex ...<|separator|>
  40. [40]
    Celotex Asbestos Trust
    Originally, Celotex was a Delaware corporation reincorporated in 1964, which manufactured and distributed roofing and building products for residential and ...Documents · DCP Settlement · Trust Online · DCP Exposure<|separator|>
  41. [41]
    Case number: 8:90-bk-10016 - Florida Middle Bankruptcy Court
    Case number: 8:90-bk-10016 - The Celotex Corporation and Carey Canada Inc. - Florida Middle Bankruptcy Court. ... 10/12/1990. Date terminated: 08/23/2017.Missing: details | Show results with:details<|separator|>
  42. [42]
    [PDF] Celotex Files for Chapter 11 Reorganization
    Since the inception of this litigation, Celotex and Carey Canada have paid out more than $587 million in settlement and defense costs for personal-injury and ...
  43. [43]
    CELOTEX CORPORATION, Petitioner, v. Bennie EDWARDS et ux.
    The filing of Celotex's bankruptcy petition on October 12, 1990, triggered the automatic stay provisions of the Bankruptcy Code. See 11 U.S.C. § 362(a). On ...Missing: details | Show results with:details
  44. [44]
    In Re: Celotex Corporation, Carey Canada Inc., Debtors.asbestos ...
    May 29, 2007 · The reorganization plan initially proposed by the Debtors in March 1996 contemplated a segregated and fixed fund for PD claims, with PI claims ...
  45. [45]
    In Re School Asbestos Litigation.the Celotex Corporation, Carey ...
    On October 12, 1990, Celotex filed for Chapter 11 bankruptcy in the United States Bankruptcy Court, Middle District of Florida, Tampa Division, at No.Missing: plan | Show results with:plan
  46. [46]
    IN RE CELOTEX CORP | 299 Fed.Appx. 850 | 11th Cir. | Judgment
    In sum, Celotex concluded in 1980 that all future asbestos litigation could impact its excess coverage. It foresaw a massive wave of property-damage litigation, ...
  47. [47]
    Administration of Settlement Trusts & Qualified Settlement Funds
    The trust was created at the conclusion of the Celotex Corporation and Carey Canada, Inc. bankruptcy proceedings, and was funded with over $1.5 billion in ...
  48. [48]
    Celotex Asbestos Trust | Payment Percentage & How to File
    Aug 25, 2025 · Founded in 1921, Celotex initially manufactured fibreboard insulation. The company rapidly expanded, opening a European division in 1925 called ...
  49. [49]
    List of Asbestos Trust Funds and Payouts
    Asbestos trust funds are court-supervised financial reserves created during bankruptcy proceedings. ... Celotex Corporation Trust, Florida, $1.5 Billion.<|control11|><|separator|>
  50. [50]
    DCP Settlement - Celotex Asbestos Trust
    Celotex Notice: re:Deemed Withdrawn Policy October 10, 2024; Notice of Payment Percentage and DCP Adjustments June 23, 2023. Quick Links. About · News · Trust ...
  51. [51]
    Asbestos Trust Fund List & Mesothelioma Fund Claim Payouts
    Oct 16, 2025 · In October 2025, $30 billion is available in asbestos trust funds established by bankrupt asbestos companies to pay mesothelioma victims.Asbestos Trust Fund List · Mesothelioma Settlement... · Mesothelioma Fund Claim...Missing: initial | Show results with:initial<|separator|>
  52. [52]
  53. [53]
    Celotex® Cemesto Board History, ingredients, maintenance, repair
    Cemesto board is the proprietary name of the first commercial sandwich board to be used in a house which was built in 1933 using sandwich panels of fibreboard ...Missing: innovation | Show results with:innovation
  54. [54]
    [PDF] Understanding the Asbestos Crisis - Yale Law School
    Eighty firms have filed for bankruptcy due to asbestos liabilities and the total cost of asbestos compensation is estimated to be more than $200 billion. This ...Missing: Celotex | Show results with:Celotex
  55. [55]
    [PDF] Asbestos Bankruptcy Trusts and Tort Compensation - RAND
    Over the past ten years, payments by asbestos bankruptcy trusts have played an increas- ingly important role in compensating asbestos injuries and have ...
  56. [56]
    [PDF] A 2021 Look At Bankruptcy Trust And Transparency Issues In ...
    May 4, 2021 · Asbestos liabilities have driven six more companies in the United States to file bankruptcy petitions since the beginning of 2020: ON Marine ...